[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 8 of about 8
1. Burvenich I, Schoonooghe S, Vervoort L, Dumolyn C, Coene E, Vanwalleghem L, Van Huysse J, Praet M, Cuvelier C, Mertens N, De Vos F, Slegers G: Monoclonal antibody 14C5 targets integrin alphavbeta5. Mol Cancer Ther; 2008 Dec;7(12):3771-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antigen 14C5 showed a similar expression to alphavbeta5 in eight different epithelial cancer cell lines (A549, A2058, C32, Capan-2, Colo16, HT-1080, HT-29, and SKBR-3).
  • We evaluated the tissue distribution of the 14C5 antigen in colon (n = 20) and lung (n = 16) cancer tissues.
  • The colon carcinoma cells stained positive for 14C5 in 50% of tumors analyzed, whereas bronchoalveolar lung carcinoma and typical carcinoid were not positive for the antigen.
  • More common types of non-small cell lung cancer, i.e., squamous (n = 5) and adenocarcinoma (n = 3), stained positive in 2 of 5 squamous carcinomas and in 1 of 3 investigated adenocarcinoma.
  • Colon (95%) and lung (50%) carcinoma tissues showed extensive expression of antigen 14C5 in the stroma surrounding the tumor cells and on the membrane of the adjacent fibroblasts.
  • We show for the first time that mAb 14C5 binds the vascular integrin alphavbeta5, suggesting that mAb 14C5 can be used as a screening agent to select colon and lung cancer patients that are eligible for anti-alphavbeta5-based therapies.
  • [MeSH-major] Antibodies, Monoclonal / physiology. Carcinoma, Non-Small-Cell Lung / therapy. Colonic Neoplasms / therapy. Gene Expression Regulation, Neoplastic. Lung Neoplasms / therapy. Receptors, Vitronectin / physiology
  • [MeSH-minor] Antigens, Neoplasm / chemistry. Cell Line, Tumor. Flow Cytometry / methods. Humans. Immunohistochemistry / methods. Protein Binding. Tissue Distribution

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19074852.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 14C5 monoclonal antibody; 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Receptors, Vitronectin; 0 / integrin alphaVbeta5
  •  go-up   go-down


2. Miquel C, Sabourin JC, Elias D, Grandjouan S, Viguier J, Ducreux M, Duvillard P, Praz F: An appendix carcinoid tumor in a patient with hereditary nonpolyposis colorectal cancer. Hum Pathol; 2004 Dec;35(12):1564-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An appendix carcinoid tumor in a patient with hereditary nonpolyposis colorectal cancer.
  • Gastrointestinal carcinoid tumors are often associated with other tumors, particularly colon adenocarcinomas; but the association between carcinoid tumors and hereditary nonpolyposis colorectal cancer (HNPCC) syndrome has not yet been explored.
  • We report an unusual case of a 28-year-old woman with HNPCC who underwent surgery for a transverse colon adenocarcinoma in whom an appendix carcinoid tumor was incidentally found.
  • To assess whether the carcinoid tumor displayed the characteristic molecular features of HNPCC tumors, we investigated the expression of mismatch-repair (MMR) proteins and microsatellite instability (MSI) status in both tumors.
  • Both tumors demonstrated normal expression of the MMR proteins hMLH1, hMSH2, hMSH6, and hPMS2.
  • Interestingly, the adenocarcinoma exhibited an MSI phenotype but the carcinoid tumor did not, indicating that these 2 tumors arose through different molecular pathways.
  • [MeSH-major] Appendiceal Neoplasms / pathology. Carcinoid Tumor / pathology. Colonic Neoplasms / pathology. Colorectal Neoplasms, Hereditary Nonpolyposis / pathology
  • [MeSH-minor] Adult. Antimetabolites, Antineoplastic / therapeutic use. Chemotherapy, Adjuvant. DNA, Neoplasm / analysis. DNA-Binding Proteins / analysis. Drug Therapy, Combination. Female. Fluorouracil / therapeutic use. Humans. Leucovorin / therapeutic use. Microsatellite Repeats / genetics. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Hereditary Cancer.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15619218.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / MSH3 protein, human; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


3. Tesei A, Ricotti L, De Paola F, Amadori D, Frassineti GL, Zoli W: In Vitro schedule-dependent interactions between the multitargeted antifolate LY231514 and gemcitabine in human colon adenocarcinoma cell lines. Clin Cancer Res; 2002 Jan;8(1):233-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In Vitro schedule-dependent interactions between the multitargeted antifolate LY231514 and gemcitabine in human colon adenocarcinoma cell lines.
  • PURPOSE: Multitargeted antifolate (MTA) and gemcitabine (GEM) have shown preclinical and clinical activity in tumor histotypes such as colon, renal, small and non-small cell lung cancers, hepatomas and carcinoid tumors.
  • In our study, we investigated the cytotoxic activity of MTA alone or in combination with GEM using different exposure schedules in three different colon cancer cell lines (LoVo, WiDr, and LRWZ).
  • The type and degree of drug interactions were not paralleled by apoptosis, which was almost always negligible, or by the type and persistency of the cell cycle perturbations.
  • CONCLUSIONS: Our results indicate that the sequential administration of GEM --> MTA provides the greatest benefit in the clinical treatment of colon cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Colonic Neoplasms / drug therapy. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Folic Acid Antagonists / therapeutic use. Glutamates / therapeutic use. Guanine / therapeutic use
  • [MeSH-minor] Apoptosis / drug effects. DNA, Neoplasm / metabolism. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Interactions. Drug Resistance, Neoplasm. Drug Therapy, Combination. Flow Cytometry. Humans. In Situ Nick-End Labeling. Pemetrexed. Thymidylate Synthase / metabolism. Tumor Cells, Cultured / drug effects

  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. GUANINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11801564.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / DNA, Neoplasm; 0 / Folic Acid Antagonists; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 0W860991D6 / Deoxycytidine; 5Z93L87A1R / Guanine; B76N6SBZ8R / gemcitabine; EC 2.1.1.45 / Thymidylate Synthase
  •  go-up   go-down


Advertisement
4. Varker KA, Campbell J, Shah MH: Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors. Cancer Chemother Pharmacol; 2008 Apr;61(4):661-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors.
  • PURPOSE: Carcinoid and islet cell tumors are known to be highly vascular.
  • There is no effective systemic therapy currently available for metastatic disease.
  • We conducted a phase II trial to evaluate the efficacy of the anti-antiangiogenic agent thalidomide in metastatic neuroendocrine tumors.
  • PATIENTS AND METHODS: Eighteen patients with measurable, histologically proven metastatic carcinoid neuroendocrine carcinomas (well-differentiated, n = 13; moderately-differentiated, n = 5) were enrolled on this study.
  • The majority of the patients had gastrointestinal primaries (small bowel, 8; pancreas, 5; colon, 1).
  • All but one patient had hepatic metastases, and 12 patients (67%) had carcinoid syndrome.
  • All patients had Eastern Cooperative Oncology Group performance status of zero or one.
  • Tumor response was assessed at 12-week intervals using RECIST criteria.
  • Planned treatment duration was 24 weeks unless unacceptable toxicity or disease progression was observed.
  • RESULTS: No patient achieved a partial remission or a complete remission.
  • Best response was stable disease (SD) in 11 of 16 response-evaluable patients (69%).
  • CONCLUSIONS: Thalidomide was fairly well tolerated in patients with metastatic carcinoid/islet cell tumors, but failed to reveal any objective responses.
  • The single stage design of the trial makes it difficult to determine whether observed SD in a subset of patients was attributable to the indolent nature of these tumors, or to beneficial effect of thalidomide.
  • [MeSH-major] Adenoma, Islet Cell / drug therapy. Angiogenesis Inhibitors / therapeutic use. Carcinoid Tumor / drug therapy. Carcinoid Tumor / secondary. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / secondary. Thalidomide / therapeutic use
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Pancreatic Hormones / blood. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17589846.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Biomarkers, Tumor; 0 / Pancreatic Hormones; 106477-83-2 / pancreastatin; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


5. Jung SH, Kim HC, Yu CS, Chang HM, Ryu MH, Lee JL, Kim JS, Kim JC: [Clinicopathologic characteristics of colorectal neuroendocrine tumor]. Korean J Gastroenterol; 2006 Aug;48(2):97-103
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic characteristics of colorectal neuroendocrine tumor].
  • BACKGROUND/AIMS: Colorectal neuroendocrine carcinoma is a rare neoplasm exhibiting fulminant progression and having poor prognosis.
  • Carcinoid tumors were excluded in this study.
  • RESULTS: Ten patients (0.2%) with colorectal neuroendocrine tumors were identified from 4,512 patients with colorectal cancer; ten neuroendocrine carcinomas and three adenocarcinomas with neuroendocrine differentiation.
  • Nine tumors were located in the rectum, two in the sigmoid, and each one in the transverse colon and cecum, respectively.
  • All patients were advanced at the time of diagnosis, with AJCC TNM staging: stage IIIB (n=2), stage IIIC (n=3), and stage IV (n=8).
  • Five patients who received chemotherapy showed median survival of 32 months (stage III) and 17.5 months (stage IV), whereas other five patients without chemotherapy died with a median survival of 6.2 months.
  • CONCLUSIONS: Colorectal neuroendocrine tumors are extremely rare showing aggressive behavior biologically, i.e fulminant early distant metastasis.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Colorectal Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Biomarkers, Tumor / immunology. Biopsy. Chromogranin A / analysis. Chromogranin A / immunology. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Sigmoid Neoplasms / drug therapy. Sigmoid Neoplasms / mortality. Sigmoid Neoplasms / pathology. Synaptophysin / analysis. Synaptophysin / immunology

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929153.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogranin A; 0 / Synaptophysin
  •  go-up   go-down


6. Ihtiyar E, Paşaoğlu O, Erkasap S, Karakaş BR, Yaşar FN: Perforated mixed carcinoid-adenocarcinoma in transverse colon and at gastroenterostomy site: case report. World J Surg Oncol; 2010;8:110
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perforated mixed carcinoid-adenocarcinoma in transverse colon and at gastroenterostomy site: case report.
  • Goblet cell carcinoid of the large intestine is a rare neoplasm, usually located in ascending colon and rectum.
  • Exploratory laparotomy revealed perforation with a diameter of 1 cm at the site of the previously performed gastroenterostomy and dilatation of the right colic flexure, secondary to a solid obstructive mass located in the mid-portion of transverse colon.
  • Histopathological investigation of the biopsies, taken from the gastroenterostomy site and the tumor, revealed mixed carcinoid-adenocarcinoma with carcinoid component, predominantly composed of goblet cells.
  • Our aim with this paper is to point out that more cases should be reported for more effective diagnosis, histopathological study, clinical investigation, treatment and prognosis of this specific neoplasm.
  • [MeSH-major] Carcinoid Tumor / pathology. Colonic Neoplasms / pathology. Gastroenterostomy. Intestinal Perforation / pathology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colon, Transverse / pathology. Combined Modality Therapy. Fluorouracil / therapeutic use. Humans. Laparotomy. Leucovorin / therapeutic use. Male. Middle Aged. Organoplatinum Compounds / therapeutic use. Prognosis

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Int. 2003 Jul;53(7):457-62 [12828611.001]
  • [Cites] Am J Surg Pathol. 1988 Aug;12(8):607-11 [3400791.001]
  • [Cites] Cancer. 1974 Aug;34(2):338-44 [4852178.001]
  • (PMID = 21176192.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Adenocarcinoid tumor; Folfox protocol
  • [Other-IDs] NLM/ PMC3014938
  •  go-up   go-down


7. Grassia R, Bodini P, Dizioli P, Staiano T, Iiritano E, Bianchi G, Buffoli F: Neuroendocrine carcinomas arising in ulcerative colitis: coincidences or possible correlations? World J Gastroenterol; 2009 Sep 7;15(33):4193-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with inflammatory bowel disease (IBD) are at increased risk of colorectal malignancies.
  • Adenocarcinoma is the commonest type of colorectal neoplasm associated with ulcerative colitis (UC) and Crohn's disease, but other types of epithelial and non-epithelial tumors have also been described in inflamed bowel.
  • With regards to non-epithelial malignancies, lymphomas and sarcomas represent the largest group of tumors reported in association with IBD, especially in immunosuppressed patients.
  • Carcinoids and in particular neuroendocrine neoplasms other than carcinoids (NENs) are rare tumors and are infrequently described in the setting of IBD.
  • We report two cases of neoplasms arising in mild left-sided UC with immunohistochemical staining for neuroendocrine markers: a large cell and a small cell neuroendocrine carcinoma of the rectum.
  • The two patients were different in age (35 years vs 77 years) and disease duration (11 years vs 27 years), and both had never received immunosuppressant drugs.
  • Although the patients underwent regular endoscopic and histological follow-up, the two neoplasms were locally advanced at diagnosis.
  • While carcinoids seem to be coincidentally associated with IBD, NENs may also arise in this setting.
  • [MeSH-major] Carcinoma, Neuroendocrine / etiology. Colitis, Ulcerative / complications. Rectal Neoplasms / etiology

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2004 Feb;47(2):163-9 [15043285.001]
  • [Cites] N Engl J Med. 2000 Sep 14;343(11):794-800 [10984569.001]
  • [Cites] Gut. 2001 Apr;48(4):526-35 [11247898.001]
  • [Cites] Histopathology. 2001 Sep;39(3):221-34 [11532032.001]
  • [Cites] Gut. 2002 Oct;51 Suppl 5:V10-2 [12221032.001]
  • [Cites] Endoscopy. 2007 Feb;39 Suppl 1:E121-2 [17440848.001]
  • [Cites] Histopathology. 1990 Jan;16(1):95-7 [2155173.001]
  • [Cites] Am J Gastroenterol. 1997 Apr;92(4):682-5 [9128324.001]
  • [Cites] J Natl Cancer Inst. 1997 Oct 1;89(19):1448-53 [9326914.001]
  • [Cites] Mod Pathol. 1998 Jun;11(6):537-42 [9647591.001]
  • [Cites] Inflamm Bowel Dis. 2005 Mar;11(3):314-21 [15735438.001]
  • [CommentIn] World J Gastroenterol. 2009 Dec 14;15(46):5882-3 [19998516.001]
  • (PMID = 19725156.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2738818
  •  go-up   go-down


8. Dörffel Y, Wermke W: Neuroendocrine tumors: characterization with contrast-enhanced ultrasonography. Ultraschall Med; 2008 Oct;29(5):506-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine tumors: characterization with contrast-enhanced ultrasonography.
  • PURPOSE: The aim of this study was to characterize the ultrasonographic features of neuroendocrine tumors (NET) and their metastases with contrast-enhanced ultrasonography (CEUS) and to compare this to clinical data.
  • MATERIALS AND METHODS: During a period of 5 years, 82 patients with 83 histologically proven NET were prospectively examined using conventional US and pulse inversion US with a second generation contrast agent (SonoVue, Contrast Pulse Sequencing) focusing on the arterial (10-20 s p. i.), capillary (20-25 sec p.i.
  • 69 patients had metastases in the abdominal tract, including eight patients with poorly differentiated neuroendocrine carcinomas with high-grade behavior.
  • In 31 patients the proliferation index (MIB-1) of the NET was < or = 2%, in 46 patients > 2%, in 6 patients > or = 20%.
  • RESULTS: In NET of the lung, stomach, and colon we found only hypoechoic or isoechoic liver metastases.
  • NET of the small intestine and pancreas represented hypoechoic, isoechoic, and/or hyperechoic liver lesions, sometimes combined.
  • Insulin producing tumors (6) had hypoechoic metastases.
  • In large NET (> 3 cm) with a proliferation index of > 2%, necrotic areas appeared spontaneously.
  • In 93% (77/83) of the cases the NET and their metastases showed an early arterial influx of microbubbles.
  • In liver metastases with a proliferation index >2%, tumor arteries showed a chaotic growth pattern.
  • In 93% (77/83) the NET lesions appeared as dark "defects" at the beginning of the late phase.
  • CONCLUSION: CEUS with CPS demonstrates typical NET imaging characteristics.
  • [MeSH-major] Contrast Media. Image Enhancement / methods. Neuroendocrine Tumors / ultrasonography
  • [MeSH-minor] Adult. Carcinoid Tumor / pathology. Carcinoid Tumor / ultrasonography. Humans. Jejunal Neoplasms / secondary. Jejunal Neoplasms / ultrasonography. Liver Neoplasms / secondary. Liver Neoplasms / ultrasonography. Middle Aged. Neoplasm Metastasis / pathology. Neoplasm Metastasis / ultrasonography. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / ultrasonography. Sensitivity and Specificity. Ultrasonography / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19241507.001).
  • [ISSN] 0172-4614
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down






Advertisement